Introduction: Hepatitis C Virus (HCV) infection affects 0.7% of the general population, and up to 40% of people prescribed Opioid Substitution Therapy (OST) in Scotland. In conventional care, less than 10% of OST users are tested for HCV and less than 25% of these initiate treatment. Community pharmacists see this group frequently to provide OST supervision. This study examines whether a pharmacist-led ‘test & treat’ pathway increases cure rates for HCV.Methods and Analysis: This protocol describes a cluster randomised trial where 60 community pharmacies provide either conventional or pharmacy-led care. All pharmacies offer dried blood spot testing (DBST) for HCV. Participants have attended the pharmacy for OST for 3 months; are positiv...
Background: Direct-acting antiviral therapy (DAAs) for hepatitis C infection (HCV) have a much small...
Background: Conventional healthcare models struggle to engage those at risk of hepatitis C virus (HC...
Background: Elimination targets for hepatitis C have been set across the world. In the UK almost 90%...
Introduction: Hepatitis C Virus (HCV) infection affects 0.7% of the general population, and up to 40...
Funding This study was funded in partnership by the Scottish Government, Gilead and Bristol-Myers Sq...
INTRODUCTION: Hepatitis C virus (HCV) infection affects 0.7% of the general population, and up to 40...
Background: Highly effective direct-acting antiviral drugs provide the opportunity to eliminate hepa...
Background: Highly effective direct-acting antiviral drugs provide the opportunity to eliminate hepa...
Background: Direct-acting antiviral therapy (DAAs) for hepatitis C infection (HCV) have a much small...
Background: Conventional healthcare models struggle to engage those at risk of hepatitis C virus (HC...
Background: Elimination targets for hepatitis C have been set across the world. In the UK almost 90%...
Introduction: Hepatitis C Virus (HCV) infection affects 0.7% of the general population, and up to 40...
Funding This study was funded in partnership by the Scottish Government, Gilead and Bristol-Myers Sq...
INTRODUCTION: Hepatitis C virus (HCV) infection affects 0.7% of the general population, and up to 40...
Background: Highly effective direct-acting antiviral drugs provide the opportunity to eliminate hepa...
Background: Highly effective direct-acting antiviral drugs provide the opportunity to eliminate hepa...
Background: Direct-acting antiviral therapy (DAAs) for hepatitis C infection (HCV) have a much small...
Background: Conventional healthcare models struggle to engage those at risk of hepatitis C virus (HC...
Background: Elimination targets for hepatitis C have been set across the world. In the UK almost 90%...